Pionyr in the News
September 28, 2021
BioCentury / The TREM2 pipeline: Date Byte
April 8, 2021
BioCentury / Macrophage therapies to watch at AACR
June 24, 2020
PharmaPhorum / Gilead to acquire half of cancer biotech Pionyr for $275m
PMLive / Gilead spends $275m on half-share in immuno-oncology firm Pionyr
June 23, 2020
San Francisco Business Times / With potential $1.8 billion deal, Gilead continues rollup of Bay Area cancer drug companies
Fierce Biotech / Gilead pens $1.5B buyout option deal for Pionyr
Xconomy / Gilead Grabs Option to Acquire Pionyr & Its Clinic-Bound Immunotherapies
Endpoints / Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech
BioWorld / Pionyr’s deal with Gilead could bring in more than $1B
BioCentury / Gilead gains access to tumor myeloid targets via Pionyr partnership
BioSpace / Gilead Continues Expansion into Oncology with Possible $1.75 Billion Deal with Pionyr
BioPharma Dive / Gilead, in latest cancer bet, puts $275M into immunotherapy startup Pionyr
Reuters Financial Post / Gilead to buy 49.9% stake in cancer drug developer for $275 mln
November 6, 2017
BioCentury / Two Faces of Myeloid